Skip to main content
OpenTrials
Completed

NCT Number: NCT02122198

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

Complaints about memory and thinking are common in women as they go through menopause and estrogen levels fall. The ovarian hormone estrogen is important for supporting normal cognitive function, and changes in brain activity and function occur when estrogen levels are decreased. Estrogen is also important for maintaining healthy blood vessels which also support normal cognitive function. In Alzheimer's disease and other types of dementia, there is significant damage to the blood vessels in the brain. This study will test whether changes in brain activity and function with the loss of estrogen are related to changes in vascular function. The investigators will measure vascular function using ultrasound, and brain activity using MRI scans in women who are enrolled in the Females, Aging, Metabolism and Exercise (FAME) study (NCT01712230). In the FAME study, healthy premenopausal women either take a medication to decrease their estrogen levels, or a placebo. This sub-study may provide new information about how estrogen affects vascular function and cognitive function, and lead to new ways to prevent or delay cognitive impairment or dementia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Volunteers will be healthy women aged 40 to 60 years
  • Are enrolled in the parent FAME study (NCT01712230).

The Investigators will consent up to 80 subjects with the aim of enrolling 17 in each of the 2 groups (placebo, GnRH agonist).

Exclusion criteria

  • mini-mental state examination (MMSE) score 27 or less
  • history of neurologic disease or major psychiatric illness
  • major depressive episode within the past 12 months
  • history of learning disability
  • less than high-school education
  • current smoking
  • use of psychoactive medications in the past 3 months (stable use of anti- depressant medication is allowed)
  • contraindications to MRI scanning

Treatment and study plan

Leuprolide Acetate

Drug

Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.

Other names: Lupron

Estradiol

Drug

Climara transdermal patch 0.075mg/day applied weekly months 6-9

Other names: Climara

medroxyprogesterone

Drug

Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.

Other names: Provera

Placebo

Drug

placebo

Primary outcomes

  1. Changes in Prefrontal Cortex Brain Activation at 6 Months

    Time frame: Baseline, 6 months

    Changes in patterns of brain activation in the prefrontal cortex using functional magnetic resonance imaging (fMRI) during a task of working memory will be measured at baseline, 6 months, and 9 months (GnRH agonist arm only). Beta weight is the percent signal change on the FMRI from one condition to another. The FMRI is measuring blood oxygen levels and blood flow in different regions of the brain and using that to determine activity changes in the brain. A positive number/increase indicates more blood flow and brain activity in that area.

  2. Changes in Prefrontal Cortex Brain Activation at 9 Months

    Time frame: Baseline, 9 months

    Changes in patterns of brain activation in the prefrontal cortex using functional magnetic resonance imaging (fMRI) during a task of working memory will be measured at baseline, 6 months, and 9 months (GnRH agonist arm only). Beta weight is the percent signal change on the FMRI from one condition to another. The FMRI is measuring blood oxygen levels and blood flow in different regions of the brain and using that to determine activity changes in the brain. A positive number/increase indicates more blood flow and brain activity in that area.

Secondary outcomes

  1. Changes in Endothelial Function at 6 Months

    Time frame: Baseline, 6 months

    Changes in endothelial function will be measured using brachial artery flow-mediated dilation at baseline, 6 months

  2. Changes in Endothelial Function at 9 Months

    Time frame: Baseline, 9 months

    Changes in endothelial function will be measured using brachial artery flow-mediated dilation at baseline, 9 months

  3. Changes in Artery Compliance at 6 Months

    Time frame: Baseline, 6 months

    Changes in carotid artery compliance will be measured using ultrasound in at baseline, 6 months.

  4. Changes in Artery Compliance at 9 Months

    Time frame: Baseline, 9 months

    Changes in carotid artery compliance will be measured using ultrasound in at baseline, 9 months.

  5. Changes in Executive Cognitive Function: Trails A, 6 Months

    Time frame: Baseline, 6 months

    Change in time (seconds) to complete Trails A test between baseline and 6 months. Negative value indicates faster time (better performance) at 6 months compared to baseline.

  6. Changes in Executive Cognitive Function: Trails A, 9 Months

    Time frame: Baseline, 9 months

    Change in time (seconds) to complete Trails A test between baseline and 9 months. Negative value indicates faster time (better performance) at 9 months compared to baseline.

  7. Changes in Executive Cognitive Function: RAVLT, 6 Months

    Time frame: Baseline, 6 months

    Change in Rey Auditory Verbal Learning Test from baseline to 6 months.

    Score is the change in the number of items correct on delayed recall trial. Scores on the RAVLT range from 0-15 with higher scores indicating better performance. A positive change indicates improvement in recall.

  8. Changes in Executive Cognitive Function: RAVLT, 9 Months

    Time frame: Baseline, 9 months

    Change in Rey Auditory Verbal Learning Test from baseline to 9 months.

    Score is the change in the number of items correct on delayed recall trial. Scores on the RAVLT range from 0-15 with higher scores indicating better performance. A positive change indicates improvement in recall.

  9. Changes in Executive Cognitive Function: Trails B, 6 Months

    Time frame: Baseline, 6 months

    Change in time (seconds) to complete Trails B test between baseline and 6 months. Negative value indicates faster time (better performance) at 6 months compared to baseline.

  10. Changes in Executive Cognitive Function: Trails B, 9 Months

    Time frame: Baseline, 9 months

    Change in time (seconds) to complete Trails B test between baseline and 9 months. Negative value indicates faster time (better performance) at 9 months compared to baseline.

  11. Changes in Executive Cognitive Function: Stroop, 6 Months

    Time frame: Baseline, 6 months

    Change in number of correct responses in one minute on Stroop Color Word Interference test between baseline and 6 months. A positive number indicates more items correct indicating better performance. There is no maximum score because the test measures how many correct responses a participant can return within one minute (minimum = 0), however 40 or fewer is considered low. The change in the number of correct responses is reported, and so a positive number indicates more correct responses and better/improved cognitive function.

  12. Changes in Executive Cognitive Function: Stroop, 9 Months

    Time frame: Baseline, 9 months

    Change in number of correct responses in one minute on Stroop Color Word Interference test between baseline and 9 months. Positive number indicates more items correct indicating better performance. There is no maximum score because the test measures how many correct responses a participant can return within one minute (minimum = 0), however 40 or fewer is considered low. The change in the number of correct responses is reported, and so a positive number indicates more correct responses and better/improved cognitive function.

  13. Changes in Executive Cognitive Function: Digits Span Forward and Backward, 6 Months

    Time frame: Baseline, 6 months

    Change in score on the Digit Span Test between baseline and 6 month. Raw scores on the Digit Span test range from 0-16 (Digits Forward) and 0-10 (Digits Backward) with higher scores indicating better performance. A positive change score indicates improved performance.

  14. Changes in Executive Cognitive Function: Digits, 9 Months

    Time frame: Baseline, 9 months

    Change in score on the Digit Span Test between baseline and 9 months. Raw scores on the Digit Span test range from 0-16 (Digits Forward) and 0-10 (Digits Backward) with higher scores indicating better performance. A positive change score indicates improved performance.

  15. Changes in Executive Cognitive Function: Controlled Oral Word Association Test, 6 Months

    Time frame: Baseline, 6 months

    Change in sum of scores on 3 COWAT trials (letters, F, A, and S) between baseline and 6 months. Participants are given one minute to think up as many words as they can associated with each letter (F, A, or S). Raw scores are the total number of words generated across all trials. Higher scores indicate more words generated and better performance. Positive change score indicates an increase in words generated, or improved performance.

  16. Changes in Executive Cognitive Function: Controlled Oral Word Association Test, 9 Months

    Time frame: Baseline, 9 months

    Change in sum of scores on 3 COWAT trials (letters, F, A, and S) between baseline and 9 months. Participants are given one minute to think up as many words as they can associated with each letter (F, A, or S). Raw scores are the total number of words generated across all trials. Higher scores indicate more words generated and better performance. Positive change score indicates an increase in words generated, or improved performance.

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Registry information

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Apr 24, 2014
Registry last updated
Jan 10, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.